ArticleMolecular oncology2026
Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer.
Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hereditary nonpolyposis colorectal cancer (HNPCC), usually termed Lynch syndrome (LS), is the most prevalent hereditary colorectal cancer syndrome, yet molecular biomarkers to differentiate nonmalignant from malignant LS cases remain limited. We performed a secondary analysis of the circulating miRNAome in 155 individuals, including healthy controls (CTRL), nonmalignant LS (H-LS), cancer-associated LS (C-LS), and sporadic colorectal cancer (CRC). We observed that LS variant heterozygotes, especially those without overt cancer, exhibit a transitional miRNAomic architecture distinct from both healthy controls and CRC patients in different age groups. Age-stratified differential expression and miRNA-mRNA network analyses revealed distinct regulatory hubs across groups. Group-specific miRNAs targeted oncogenic, immune, and DNA repair pathways. The analysis suggested that nonmalignant LS variant heterozygotes occupy a circulating miRNAome state distinct from both healthy controls and overt CRC, whereas C-LS and sporadic CRC shared selected malignant-associated miRNA features. To assess external concordance, we performed orthogonal validation of a prespecified six-miRNA panel in the independent GSE30454 primary colorectal tissue cohort, comprising normal, LS, sporadic MSI, and MSS samples. The composite panel preserved disease-axis structure across the external cohort, with strongest discrimination in biologically relevant mismatch repair-related contrasts. These findings suggest candidate circulating miRNA molecular states across LS and sporadic colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.